Comparison of the NPY receptors mediating vasoconstriction of the guinea-pig uterine artery and thoracic vena cava using a range of NPY analogues.
The ability of analogues of neuropeptide Y (NPY) to produce direct vasoconstriction, or to antagonize NPY constrictions, was examined in isolated segments of the thoracic vena cava and the uterine artery of guinea-pigs, where NPY mediates a slow phase of sympathetic vasoconstriction. [Leu31,Pro34]NPY, NPY(13-36) and NPY(18-36) all contracted the uterine artery and the vena cava. Contractions produced by [Leu31,Pro34]NPY were similar in time course to those produced by porcine NPY (pNPY), although contractions produced by NPY(13-36) or NPY(18-36) typically were slower than pNPY contractions. In both vessels the order of potency of the agonists was pNPY > or = [Leu31,Pro34]NPY > NPY(13-36) > NPY(18-36). High concentrations (10(-5)mol.l-1) of pNPY or [Leu31,Pro34]NPY produced desensitization of contractions of the uterine artery produced by NPY(13-36). The reported NPY receptor antagonists, PYX-1 and PYX-2 (5 x 10(-6)mol.l-1), slightly reduced (by 21-47%) the magnitude of constrictions produced by exogenous pNPY (1-3 x 10(-8) mol.l-1) in both the uterine artery and the vena cava. These results show that the NPY receptors mediating slow sympathetic vasoconstriction of both the uterine artery and the vena cava are likely to be predominantly Y1 receptors, despite differences between the adrenoceptors mediating sympathetic responses in the two blood vessels.
Morris
J L
JL
Department of Anatomy and Histology, School of Medicine, Flinders University, Adelaide, Australia.
Sabesan
S
S
D000818:Animals; D005260:Female; D006168:Guinea Pigs; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D011942:Receptors, Adrenergic, alpha / Q000502:physiology; D017476:Receptors, Neuropeptide Y / Q000145:classification / Q000187:drug effects* / Q000502:physiology; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D014599:Uterus / Q000098:blood supply*; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D014683:Vena Cava, Superior / Q000187:drug effects* / Q000502:physiology
D009478:Neuropeptide Y; D010446:Peptide Fragments; D011942:Receptors, Adrenergic, alpha; D017476:Receptors, Neuropeptide Y; C062924:neuropeptide Y (13-36); C059889:neuropeptide Y (18-36); C062259:neuropeptide Y, Leu(31)-Pro(34)-